HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer

NCT05751850 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

778

Enrollment

INDUSTRY

Sponsor class

Conditions

First-line Treatment of Advanced Pancreatic Cancer

Interventions

DRUG: HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate
DRUG: nab-paclitaxel; gemcitabine

Sponsor

Jiangsu HengRui Medicine Co., Ltd.